Revenio Group Corporation | Stock Exchange Release | October 14, 2026 at 14:00:00 EEST
On 14 September 2026, Revenio Group announced the composition of its Shareholders’ Nomination Board. The company has today been informed that Caravelle Capital SAS is changing its representative on the Nomination Board. Effective 14 October 2026, Caravelle Capital SAS’s new representative is Jérémie Leroy.
The composition of the Nomination Board as of 14 October 2026:
- Casper Lorenzen, Investment Director, William Demant Invest A/S (appointed by William Demant Invest A/S), Chair
- Jérémie Leroy, CFO, Clipper Group (appointed by Caravelle Capital SAS)
- Mira Mielonen, Senior Responsible Investment Specialist, Ilmarinen Mutual Pension Insurance Company (appointed by Ilmarinen Mutual Pension Insurance Company)
- Ville Kivipelto, Chief Portfolio Manager, Danske Invest Finnish Equity Fund (appointed by Danske Invest Finnish Equity Fund)
The Chair of the company’s Board of Directors, Arne Boye Nielsen, serves as an expert member of the Nomination Board without membership or voting rights.
The Shareholders’ Nomination Board of Revenio Group Corporation is responsible for preparing proposals concerning the election and remuneration of the members of the Board of Directors for the Annual General Meeting and, where necessary, for an Extraordinary General Meeting. The Nomination Board will submit its proposal to the company’s Board of Directors by 31 January 2027 at the latest. The Nomination Board is appointed annually.
For further information, please contact
CEO Jouni Toijala
+358 50 484 0085
jouni.toijala@revenio.fi
Distribution
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Main media
www.reveniogroup.fi/en
Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.
In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. In 2025, the Group’s pro forma net sales totaled EUR 252.8 million, with a pro forma adjusted EBITDA of EUR 45.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.